ArticleInternational microbiology : the official journal of the Spanish Society for Microbiology2026
Harnessing the seaweed holobiont: antibacterial and antioxidant lead compounds from epiphytic microbiota.
Article in International microbiology : the official journal of the Spanish Society for Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antibacterial activity of marine macroalgae-associated Bacillus spp. from the Bay of Bengal coast of India.Antonie van Leeuwenhoek · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Seaweed-associated epiphytic bacteria represent a promising source of bioactive metabolites with antimicrobial and antioxidant properties. In this study, 26 culturable epiphytic bacterial isolates were obtained from five marine macroalgae, namely Ulva lactuca, Amphiroa anceps, Halimeda opuntia, Kappaphycus alvarezii, and Sargassum wightii. Preliminary screening using the agar overlay method revealed that six isolates (EB-30, EB-38, EB-42, EB-47, EB-48, and EB-50) exhibited antibacterial activity against at least two pathogenic test strains, accounting for 23% of the total isolates. Crude extracellular extracts demonstrated inhibitory effects in the disc diffusion assay, with inhibition zones ranging from 8 to 21 mm at 1 mg/mL. Among these, EB-38 showed the strongest antibacterial activity against Bacillus subtilis MTCC 441, Staphylococcus aureus MTCC 96, and Klebsiella pneumoniae MTCC 432, with minimum inhibitory concentrations ranging from 62.5 to 250 µg/mL. Antioxidant activity assessed by the DPPH radical scavenging assay showed concentration-dependent effects, with EB-38 extract exhibiting the highest scavenging efficiency (71.13 ± 1.03%) and the lowest IC₅₀ value (0.41881 ± 0.02544 mg/mL). Total phenolic content ranged from 7.7 ± 0.78 to 16.98 ± 1.73 mg GAE/g extract. Molecular identification based on partial 16 S rRNA gene sequencing revealed the isolates as Halobacillus sp. (EB-30), Exiguobacterium aestuarii (EB-38), Bacillus licheniformis (EB-42), Rossellomorea aquimaris (EB-47), Bacillus sp. (EB-48), and Pseudomonas sp. (EB-50). GC–MS analysis revealed bioactive compounds, including Pyrrolo[1,2-a] pyrazine-1,4-dione derivatives, fatty acid methyl esters, tert-butylated phenols, and 13-Docosenamide. However, further mechanistic investigations are required to elucidate the molecular basis of the observed antibacterial and antioxidant effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.